Citi Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125
Merck & Co Analyst Ratings
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
TD Cowen Adjusts Price Target on Merck to $121 From $140
Optimistic Buy Rating for Merck & Co. Driven by Winrevair Projections and Financial Strength
Merck Is Maintained at Equal-Weight by Morgan Stanley
Merck & Co Analyst Ratings
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $113
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $122
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $125
BMO Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $105
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Merck Is Maintained at Outperform by Leerink Partners
Merck & Co Analyst Ratings
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Bernstein Sticks to Their Hold Rating for Merck & Company (MRK)
Major banks rating | Truist: The biopharmaceutical Industry needs more mergers and acquisitions to recover, lowering Merck's Target Price to $110.
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $120
Truist Financial Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110